Investors

Investor Presentation February 2020

2019 Annual General Meeting

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc to Present at the Cowen and Company 40th Annual Healthcare Conference

02/27/20

DUBLIN, Ireland and TREVOSE, Pa. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that John...

Read More
Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

02/25/20

~ KEVEYIS ® (dichlorphenamide) Full-Year 2019 Revenue of $21.7 Million , a 29 Percent Increase over 2018 Revenue of $16.8 Million ~ ~ Full-Year 2020 KEVEYIS ® (dichlorphenamide) Revenue Guidance of Approximately $26 to $27 Million ; Company Anticipates Continued Positive and Growing Contribution...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc to Present at the Cowen and Company 40th Annual Healthcare Conference

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

Upcoming Events